New Board of Directors Appointments
Sherbrooke, Qc, CA, January 15th, 2020 – Immune Biosolutions, an early-stage biopharmaceutical company focusing on the discovery, engineering and development of therapeutic humanized chicken antibodies, today announced the appointments of Drs. Nadine Beauger and Louise Proulx to its Board of Directors.
Dr. Beauger is currently Chief Executive Officer at IRICoR—a drug discovery-focused Centre of Excellence in Commercialization and Research, based at Université de Montréal’s Institute for Research in Immunology and Cancer (IRIC). Dr. Beauger has held various senior roles within the biopharma industry, namely at the boutique IP firm Robic, and at the California-based VantagePoint Capital Partners. “The Immune Biosolutions team leads insightful and highly innovative research. It is exciting for me to join the Board of such a dynamic group. I look forward to sharing my insights about the development of new therapeutic pipelines in oncology and immunology based on the company’s technology,” noted Dr. Beauger.
Dr. Louise Proulx is a science executive with years of experience in the drug development industry. Most recently, she has served as the Co-Founder of Therillia Development Company and a Venture Partner with Sanderling Ventures. Dr. Proulx has held the position of Vice-President, Product Development at BioChem Pharma—Canada’s largest pharmaceutical company, which was sold to Shire Pharmaceuticals for $5B in 2000. She has also served in the same role at ViroChem Pharma prior to its acquisition by Vertex Pharmaceuticals, at which point she took on the position of Site Head at Vertex Canada. “I am excited to join this organization on their mission to treat, and hopefully cure, difficult-to-treat cancers and expand the use of humanized chicken antibodies for other important therapeutic areas”, commented Dr. Proulx.
Dr. Frédéric Leduc, Chief Executive Officer and Co-Founder of Immune Biosolutions is thrilled to welcome Drs. Beauger and Proulx to the company’s Board of Directors. “Dr. Beauger brings a wealth of drug development expertise in oncology and immunology to Immune Biosolutions. Her experience in early- and late-stage pharmaceutical product development will add significant value to our company as we work to bring new therapeutic antibodies to the market to help extend and improve the lives of patients”, he said. He added, “Dr. Proulx brings an impressive track record in drug discovery and development and has extensive experience in innovation management. Her product development expertise will be immensely helpful as we push forward with our therapeutic pipelines.”
“We look forward to their leadership and guidance as independent members of our Board”, commented Dr. Bruno Maranda, Director of the Board of Immune Biosolutions.
About Immune Biosolutions
Immune Biosolutions, headquartered in Sherbrooke, Canada, is an early-stage biopharmaceutical company focused on the discovery, engineering and development of humanized chicken antibodies that target intractable membrane proteins with a validated therapeutic potential. Immune Biosolutions’ current pipeline of therapeutic programs includes antibody molecules against several GPCRs—traditionally difficult-to-target membrane proteins that are known to be over-expressed in several cancers.
